Cordyceps Sunshine Biotech Holdings (RAJAF) Invested Capital (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Invested Capital history runs 5 years deep, the most recent figure standing at $465233.0 for Q4 2025.

• In Q4 2025, Invested Capital rose 3.81% year-over-year to $465233.0; the TTM figure through Dec 2025 stood at $913388.0 (down 50.21% YoY), while the FY2025 annual figure was $465233.0, up 3.81% from the prior year.
• Invested Capital for Q4 2025 stood at $465233.0, up from $448155.0 in the prior quarter.
• The five-year high for Invested Capital was $1.6 million in Q4 2021, with the low at $448155.0 in Q4 2024.
• The 4-year median for Invested Capital is $925868.5 (2022), against an average of $967794.0.
• The sharpest annual moves came in 2021 and 2022: Invested Capital increased 22.23% in 2021, then declined 11.76% in 2022.
• Cordyceps Sunshine Biotech Holdings' Invested Capital stood at $1.6 million in 2021, then fell by 11.76% to $1.4 million in 2022, then plunged by 67.68% to $448155.0 in 2024, then rose by 3.81% to $465233.0 in 2025.
• Business Quant data shows RAJAF's Invested Capital at $465233.0 in Q4 2025, $448155.0 in Q4 2024, and $1.4 million in Q4 2022.